The CLARITY biomaterial was evaluated for its therapeutic capability when loaded with either 100 μg_anti-CD40 monoclonal antibody or 800 μg_Caflanone drug against a no-treatment group of C57BL6 mice bearing subcutaneous pancreatic tumors. Here, CD40 is linked to pancreatic neoplasm.